It is now accepted that NSCLC bearing different KRAS mutations are heterogenous resulting from factors such as varying levels of KRAS activation (GTP-bound KRAS), upregulation of distinct pro-tumorigenic functions and contextual acquisition of secondary mutations exclusive to each KRAS mutation [8–11]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.